Grassley to APA: Open your books

Written byBob Grant

| 2 min read

Senator linkurl:Charles Grassley;http://www.the-scientist.com/news/display/53381/ (R-IA), ranking member of the Senate Finance Committee, issued a stark warning to the American Psychiatric Association on Thursday (July 10): Clearly outline the pharmaceutical industry's financial influence on your workings or incur my wrath! Well, maybe Grassley didn't use those __exact__ words. "I have come to understand that money from the pharmaceutical industry can shape the practices of non-profit organizations which purport to be independent in their viewpoints and actions," Grassley wrote in a linkurl:letter;http://finance.senate.gov/press/Gpress/2008/prg071008h.pdf to APA CEO linkurl:James Scully.;http://pn.psychiatryonline.org/cgi/content/full/41/1/4 "I would appreciate an accounting of industry funding that pharmaceutical companies and/or the foundations established by these companies have provided to the American Psychiatric Association (APA)." Grassley's language my be genial - as it tends to be in letters volleyed between the Senate conflict of interest hunter and his quarry - but his message is clear. The Senator has spent the better part of this year rooting out potential financial conflicts among prominent researchers and physicians (especially linkurl:psychiatrists),;http://www.the-scientist.com/blog/display/54771/ and now he wants to know exactly how intertwined pharma is with the top professional psychiatry organization in the country. Grassley not only wants to know which pharma company contributed how much to the APA since 2003, he wants the group to lay out its policies for accepting industry funds. The APA responded on Friday (July 11) to Grassley's request by sending an Email to its 148,000 members, as linkurl:reported;http://www.pharmalot.com/2008/07/grassley-probes-psychiatrists-over-ties-to-pharma/ by Ed Silverman over at the Pharmalot blog. The Email stated that the association will fully comply with Grassley and assured members that it has always held itself to a high standard regarding pharma funding. "The APA fully endorses the concept of transparency in our relationships with pharma and other entities and has been in the forefront of the disclosure process," the Email read. "In March, 2008, long before this inquiry from Senator Grassley, your Board of Trustees empaneled a working group charged to review all APA pharmaceutical revenues, sort them into categories; and provide the Board with options for ending pharmaceutical support in each category and the implications for the activities they currently fund."

Meet the Author

Bob Grant

From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

View Full Profile

Grassley to APA: Open your books

The Scientist ARCHIVES

Become a Member of

Related Topics

Meet the Author

Bob Grant

Related Research Resources

Why Do We Feel Butterflies in the Stomach?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Long-Read RNA Sequencing Reveals a Regulatory Role for Splicing in Immunotherapy Responses

Research Roundtable: The Evolving World of Spatial Biology

Exploring the State of the Art in Gene Editing Techniques

Simplifying Early Alzheimer’s Disease Diagnosis with Blood Testing

Products

Product News

Research on rewiring neural circuit in fruit flies wins 2025 Eppendorf & Science Prize

EVIDENT's New FLUOVIEW FV5000 Redefines the Boundaries of Confocal and Multiphoton Imaging

EVIDENT Launches Sixth Annual Image of the Year Contest

10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research